Evidence map›Paper›PMID 42723174›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Multifunctional Nanovaccine-Radiotherapy Synergy Drives Anti-Tumor Immunity via Multi-Cascade Cell Death for Pancreatic Cancer Therapy.

Chengyi Huang, Yushu Han, Xiang Liu, Chuanhao Wang, Xiaofei Zhu, Di Chen, Yangyang Gong, Liang Chen, Wenjuan Chen, Zhenyuan Miao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chengyi Huang *Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.ORCID https://orcid.org/0009-0002-3717-4939
Yushu Han *Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Xiang Liu *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0002-5964-9248
Chuanhao WangSchool of Pharmacy, Naval Medical University, Shanghai, China.
Xiaofei ZhuDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0001-5769-9308
Di ChenDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Yangyang GongDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Liang ChenDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Wenjuan ChenDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.
Zhenyuan MiaoSchool of Pharmacy, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0001-7839-4183
Bufu TangDepartment of Interventional Radiology, Shanghai Institute of Medical Imaging, Shanghai Institution of Medical Imaging, Zhongshan Hospital, Shanghai, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.ORCID https://orcid.org/0009-0003-0872-2956
Huojun ZhangDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, China.ORCID https://orcid.org/0009-0003-4327-3498

Funding

National Natural Science Foundation of China 82272742 82173743 82473233National Natural Science Foundation of China 82303680Shanghai Health Commission Leading Talent Program 2022LJ019
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PAAD) is an immunosuppressive malignancy refractory to radiotherapy and immunotherapy. Conventional tumor vaccines fail in PAAD due to a suppressive tumor microenvironment (TME), inadequate antigen presentation, and impaired immunogenic cell death (ICD). Using a machine learning-driven transcriptomic analysis, we identified FSTL3 as a vital TME regulatory factor enriched in desmoplastic pancreatic lesions and constructed a cRGD-modified liposomal carrier co-encapsulating gemcitabine and siFSTL3 (siFSTL3/Lip

Indexed as

ferroptosisFSTL3immunogenic cell deathnanovaccinepancreatic cancerradiotherapytumor microenvironment

Identifiers

PMID42723174
PMCPMC13562777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.